|
Video: What is a Stock Split?
|
|
Cogent Biosciences is a biotechnology company focused on developing therapies for genetically defined diseases. Co.'s approach is to design therapies that treat the underlying cause of disease and improve the lives of patients. Co.'s main program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. Bezuclastinib is a highly selective KIT inhibitor with the potential to provide a new treatment option for these patient populations. In addition, Co.'s research team is developing a portfolio of targeted therapies to help patients fighting serious, genetically driven diseases. According to our COGT split history records, Cogent Biosciences has had 1 split. | |
|
Cogent Biosciences (COGT) has 1 split in our COGT split history database. The split for COGT took place on November 09, 2020. This was a 1 for 4 reverse split, meaning for each 4 shares of COGT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as Cogent Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the COGT split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cogent Biosciences shares, starting with a $10,000 purchase of COGT, presented on a split-history-adjusted basis factoring in the complete COGT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/02/2018 |
|
End date: |
04/17/2024 |
|
Start price/share: |
$43.00 |
|
End price/share: |
$6.53 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-84.81% |
|
Average Annual Total Return: |
-26.78% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,518.71 |
|
Years: |
6.05 |
|
|
|
Date |
Ratio |
11/09/2020 | 1 for 4 |
|
|